Latest Microbiome Testing News

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.